

# Understanding Surgical and Traumatic Coagulopathy: Computation Meets Experiment

Alexander Y. Mitrophanov, PhD

Senior Statistician  
Frederick National Laboratory for Cancer Research  
National Institutes of Health  
Frederick, MD  
[mitrophanovay@yahoo.com](mailto:mitrophanovay@yahoo.com)

Johns Hopkins University  
Department of Anesthesiology and Critical Care Medicine  
Grand Rounds  
8 October 2020

# Surgical and traumatic coagulopathy



# Surgical and traumatic coagulopathy



Computational modeling  
(simulations)

Systems biology


Laboratory experiments

Systems medicine?

Clinical practice




# Coagulopathy is multifactorial



# Thrombin generation *in vitro*

---


Normal thrombin generation




Thrombin → fibrin → blood clot

# Thrombin generation *in vitro*

Normal thrombin generation




Coagulopathy




Thrombin → fibrin → blood clot

# Therapeutic solutions for diverse scenarios

Normal thrombin generation




Coagulopathy



Thrombin → fibrin → blood clot

# Thrombin-generation quantification



Mitrophanov et al., *J Trauma* (2012)

**CT:** clotting (lag) time

**PH:** thrombin peak height


**AUC:** area under the curve

**MS:** maximum slope

**PH:** peak height



# Large system: intuition alone is not enough




Mitrophanov et al., *Mol BioSyst* (2014)

- How can we anticipate the effects of coagulopathy on thrombin generation?
- How do we know what coagulation factors are key?


# Approach: model computationally and then test

## Blood coagulation system



# Approach: model computationally and then test

## Blood coagulation system




## Computational kinetic modeling

$C(t)$  = species concentration;  
 $dC(t)/dt = (\text{production rate})$   
 $- (\text{depletion rate})$

# Approach: model computationally and then test

Blood coagulation system



*In vitro* experiments  
(plasma or whole blood)




Computational kinetic modeling

$C(t)$  = species concentration;  
 $dC(t)/dt = (\text{production rate}) - (\text{depletion rate})$

# Approach: model computationally and then test

## Blood coagulation system




## *In vitro* experiments (plasma or whole blood)




## Computational kinetic modeling

$C(t)$  = species concentration;  
 $dC(t)/dt$  = (production rate)  
- (depletion rate)




## Comparison: validation



# Approach: model computationally and then test

Blood coagulation system




*In vitro* experiments  
(plasma or whole blood)



Computational kinetic modeling

$$C(t) = \text{species concentration};$$
$$dC(t)/dt = (\text{production rate}) - (\text{depletion rate})$$


Comparison: validation



Learning


# Simulations can reproduce experimental results

Undiluted plasma




# Simulations can reproduce experimental results

Undiluted plasma



3-fold dilution




**Dilution reduces peak height**



# Hypothermia: simulated effects for the “average” subject


## Hypothermia at 33 °C



37 °C (normal) prediction  
33 °C prediction range  
33 °C prediction quartiles  
33 °C prediction median


# Hypothermia: simulated effects for the “average” subject

## Hypothermia at 33 °C



37 °C (normal) prediction  
33 °C prediction range  
33 °C prediction quartiles  
33 °C prediction median


## Varied temperature



Peak height practically unchanged

# Hypothermia: experimental validation


## Thrombin peak height




Undiluted 3-fold dilution 5-fold dilution  
Dashed: 15 nM thrombomodulin

# Hypothermia: experimental validation

## Thrombin peak height



## Area under the curve




Undiluted 3-fold dilution 5-fold dilution  
Dashed: 15 nM thrombomodulin

**Hypothermia inhibits  
anticoagulant mechanisms**

# FVIIa supplementation skews thrombin generation

Simulations for the “average” subject\*




**(r)FVIIa** = (recombinant) activated Factor VII


\*Mitrophanov et al., *J Trauma* (2012)

# FVIIa supplementation skews thrombin generation

Simulations for the “average” subject\*



Experimental data\*\*




**(r)FVIIa** = (recombinant) activated Factor VII

\*Mitrophanov et al., *J Trauma* (2012)

\*\*Mitrophanov et al., *Anesth Analg* (2016)

# PCC-AT: thrombin-generation normalization

Simulations for the “average”  
subject\*




**(r)FVIIa** = (recombinant) activated Factor VII  
**PCC-FVII** = FII + FIX + FX + FVII  
**PCC-AT** = FII + FIX + FX + antithrombin (AT)


\*Mitrophanov et al., *J Trauma* (2012)

# PCC-AT: thrombin-generation normalization

Simulations for the “average” subject\*



Experimental data\*\*



**(r)FVIIa** = (recombinant) activated Factor VII

**PCC-FVII** = FII + FIX + FX + FVII

**PCC-AT** = FII + FIX + FX + antithrombin (AT)


\*Mitrophanov et al., *J Trauma* (2012)

\*\*Mitrophanov et al., *Anesth Analg* (2016)



# Fibrin generation: simulations and validation

## Prothrombin titration




**Lines:** model simulations

**Squares:** experimental data


prothrombin  $\rightarrow$  thrombin  $\left( \begin{array}{l} \text{fibrinogen} \\ \text{fibrin} \rightarrow \text{blood clot} \end{array} \right.$

# Fibrin generation: simulations and validation

## Prothrombin titration



## Fibrinogen titration



**Lines:** model simulations


**Squares:** experimental data

prothrombin  $\rightarrow$  thrombin  $\left( \begin{array}{l} \text{fibrinogen} \\ \text{fibrin} \rightarrow \text{blood clot} \end{array} \right.$

# Fibrinogen (Fg) + PCC-AT restore normal thrombin and fibrin generation in diluted plasma

Model simulations for the “average” subject

Fibrin




Dilution: 3-fold


# Fibrinogen (Fg) + PCC-AT restore normal thrombin and fibrin generation in diluted plasma

Model simulations for the “average” subject

Fibrin




Thrombin



Dilution: 3-fold


# Adding flow: whole blood *in vitro*

## Microfluidic device




# Adding flow: whole blood *in vitro*

## Microfluidic device




## Fibrin generation: simulation and experiment



**Platelet deposition: similar**


# Coagulation factors + fibrinogen enhance coagulation in diluted blood

Clot resistance to flow  
(the flow slows down accordingly)



**PCC = FII + FIX + FX**

# Antithrombin improves PCC effects in a porcine model of traumatic coagulopathy





# CONCLUSIONS

---

- Computational modeling can effectively guide experimentation in blood-coagulation research
- Thrombin generation may be normalized by a few pro/anti-coagulant factors (**balanced intervention**)
- Additional supplementation of fibrinogen may be useful

# ACKNOWLEDGEMENTS

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.  
DoD Biotechnology HPC Software Applications Institute (BHS AI)

Vijay Govindarajan (BHS AI)  
Jaques Reifman (BHS AI)  
Frits Rosendaal (Leiden)  
Fania Szlam (Emory)  
Roman Sniecinski (Emory)  
Jerrold Levy (Duke)

## **Funding**

U.S. Army Medical Research and Development Command  
DoD High Performance Computing Modernization Program